UA110096C2 - Комбінована терапія нефукозильованим анти-cd20 антитілом з бендамустином - Google Patents

Комбінована терапія нефукозильованим анти-cd20 антитілом з бендамустином

Info

Publication number
UA110096C2
UA110096C2 UAA201202678A UAA201202678A UA110096C2 UA 110096 C2 UA110096 C2 UA 110096C2 UA A201202678 A UAA201202678 A UA A201202678A UA A201202678 A UAA201202678 A UA A201202678A UA 110096 C2 UA110096 C2 UA 110096C2
Authority
UA
Ukraine
Prior art keywords
bendamustine
fucosyled
antibody
combined therapy
cancer
Prior art date
Application number
UAA201202678A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110096(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA110096C2 publication Critical patent/UA110096C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201202678A 2009-08-14 2010-12-08 Комбінована терапія нефукозильованим анти-cd20 антитілом з бендамустином UA110096C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14
PCT/EP2010/004939 WO2011018224A1 (en) 2009-08-14 2010-08-12 Combination therapy of an afucosylated cd20 antibody with bendamustine

Publications (1)

Publication Number Publication Date
UA110096C2 true UA110096C2 (uk) 2015-11-25

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201202678A UA110096C2 (uk) 2009-08-14 2010-12-08 Комбінована терапія нефукозильованим анти-cd20 антитілом з бендамустином

Country Status (34)

Country Link
US (4) US20110165151A1 (ru)
EP (1) EP2464382B1 (ru)
JP (3) JP5646626B2 (ru)
KR (1) KR101425736B1 (ru)
CN (2) CN107261138A (ru)
AR (1) AR077866A1 (ru)
AU (1) AU2010281866B2 (ru)
BR (1) BR112012002855A2 (ru)
CA (1) CA2769674C (ru)
CL (1) CL2012000391A1 (ru)
CR (1) CR20120036A (ru)
CY (2) CY1119251T1 (ru)
DK (1) DK2464382T3 (ru)
ES (1) ES2630158T3 (ru)
HK (1) HK1245145A1 (ru)
HR (1) HRP20170972T1 (ru)
HU (2) HUE033531T2 (ru)
IL (1) IL217753A (ru)
LT (2) LT2464382T (ru)
LU (1) LUC00045I2 (ru)
MA (1) MA33469B1 (ru)
MX (2) MX355849B (ru)
MY (1) MY163003A (ru)
NO (1) NO2017054I1 (ru)
NZ (1) NZ597666A (ru)
PL (1) PL2464382T3 (ru)
PT (1) PT2464382T (ru)
RS (1) RS56146B1 (ru)
SG (1) SG178324A1 (ru)
SI (1) SI2464382T1 (ru)
TW (1) TWI409079B (ru)
UA (1) UA110096C2 (ru)
WO (1) WO2011018224A1 (ru)
ZA (1) ZA201200830B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03330B (me) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
DK2176296T3 (da) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
MX351557B (es) 2008-01-31 2017-10-19 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
MX354479B (es) * 2011-08-16 2018-03-07 Morphosys Ag Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
SI2744826T1 (sl) * 2011-08-16 2022-05-31 Morphosys Ag Kombinirana terapija s protitelesom proti CD19 in analogom purina
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
UA119443C2 (uk) 2013-06-07 2019-06-25 Нордік Нановектор Аса Спосіб підвищення регуляції експресії антигену
JP6528779B2 (ja) 2014-03-25 2019-06-12 小野薬品工業株式会社 びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2016163531A1 (ja) 2015-04-09 2016-10-13 小野薬品工業株式会社 プリノン誘導体の製造方法
ES2777602T3 (es) 2015-08-03 2020-08-05 Engmab Sàrl Anticuerpos monoclonales contra el antígeno de maduración de células b humanas (BCMA)
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN112399848A (zh) 2018-05-23 2021-02-23 细胞基因公司 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP3284753B1 (en) 2002-10-17 2019-06-05 Genmab A/S Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
DK1572744T3 (da) 2002-12-16 2010-09-20 Genentech Inc Immunoglobulinvarianter og deres anvendelser
SG2013005590A (en) 2003-01-22 2015-06-29 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
EP1628531A4 (en) * 2003-05-16 2010-06-30 Idera Pharmaceuticals Inc SYNERGISTIC TREATMENT OF CANCER BY COMMON USE OF IMMUNOMER AND CHEMOTHERAPEUTICS
AU2004261229A1 (en) 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
ME03330B (me) * 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CA2605697A1 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
SG192479A1 (en) 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
PL1945666T3 (pl) * 2005-10-21 2013-09-30 Genzyme Corp Przeciwciała o wzmocnionej aktywności zależnej od przeciwciał cytotoksyczności komórkowej, sposoby ich wytwarzania i zastosowanie
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
WO2010083365A1 (en) * 2009-01-16 2010-07-22 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
WO2010120288A1 (en) * 2009-04-15 2010-10-21 Invista Technologies S.A R.L. Improving miscibility of otherwise immiscible compounds

Also Published As

Publication number Publication date
CA2769674A1 (en) 2011-02-17
IL217753A0 (en) 2012-03-29
CY1119251T1 (el) 2018-02-14
SI2464382T1 (sl) 2017-08-31
PT2464382T (pt) 2017-06-30
JP5963013B2 (ja) 2016-08-03
CR20120036A (es) 2012-04-18
EP2464382B1 (en) 2017-05-03
NO2017054I1 (no) 2017-10-26
AU2010281866A1 (en) 2012-02-02
LTPA2017035I1 (lt) 2017-11-27
CY2017034I2 (el) 2018-02-14
US20150093376A1 (en) 2015-04-02
NZ597666A (en) 2013-10-25
TW201110980A (en) 2011-04-01
MX2012001782A (es) 2012-04-19
KR20120054068A (ko) 2012-05-29
WO2011018224A1 (en) 2011-02-17
US20110165151A1 (en) 2011-07-07
HK1245145A1 (zh) 2018-08-24
HUE033531T2 (hu) 2021-12-28
CL2012000391A1 (es) 2012-08-24
DK2464382T3 (en) 2017-07-17
HUS1700041I1 (hu) 2017-11-28
US20140044705A1 (en) 2014-02-13
MA33469B1 (fr) 2012-07-03
CN107261138A (zh) 2017-10-20
ZA201200830B (en) 2012-10-31
JP5646626B2 (ja) 2014-12-24
IL217753A (en) 2016-10-31
SG178324A1 (en) 2012-03-29
BR112012002855A2 (pt) 2016-11-01
JP2013501740A (ja) 2013-01-17
LT2464382T (lt) 2017-07-25
AU2010281866B2 (en) 2016-05-12
RS56146B1 (sr) 2017-11-30
CA2769674C (en) 2018-01-23
KR101425736B1 (ko) 2014-08-01
AR077866A1 (es) 2011-09-28
MX355849B (es) 2018-05-02
JP2015071611A (ja) 2015-04-16
LUC00045I1 (ru) 2017-11-03
RU2012109445A (ru) 2013-09-27
CN102596245A (zh) 2012-07-18
HRP20170972T1 (hr) 2017-09-22
MY163003A (en) 2017-07-31
LUC00045I2 (ru) 2018-02-26
US20120315268A1 (en) 2012-12-13
TWI409079B (zh) 2013-09-21
PL2464382T3 (pl) 2017-09-29
US20160166688A9 (en) 2016-06-16
JP2016222673A (ja) 2016-12-28
EP2464382A1 (en) 2012-06-20
CY2017034I1 (el) 2018-02-14
HUS000498I2 (hu) 2021-03-29
ES2630158T3 (es) 2017-08-18

Similar Documents

Publication Publication Date Title
UA110096C2 (uk) Комбінована терапія нефукозильованим анти-cd20 антитілом з бендамустином
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
AR098328A1 (es) Terapia de combinación de un anticuerpo anti cd20 con un inhibidor de btk
AR096184A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco
IL212998A (en) Use of anti-vegf antibody to prepare a drug for use in combination with chemotherapy to treat breast cancer
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
TN2015000396A1 (en) Antibody drug conjugates
WO2014177615A3 (en) COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
UA101487C2 (en) Humanized b-ly1 antibody formulation
ECSP099440A (es) Anticuerpos contra el receptor del factor de crecimiento similar a la insulina i y la utilización de los mismos
CL2012001853A1 (es) Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
NZ598127A (en) Cancer metastasis inhibitor
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
CL2014001282A1 (es) Uso de un inmunoconjugado de un anticuerpo dirigido contra el receptor del factor de crecimiento epidérmico (egfr) para el tratamiento del cáncer resistente al tratamiento dirigido contra egfr, donde el inmunoconjugado es un anticuerpo enlazado a un agente citotóxico.
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
IL218637A0 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
BRPI0809079A2 (pt) tratamento de câncer com um combinado de il-18 humana e anticorpo anti-cd20
EP2455102A4 (en) CANCER THERAPEUTIC AGENT COMPRISING AN ANTIBODY AGAINST CANCER SPECIFIC MEMBRANE ANTIGEN
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
TH136427A (th) การบำบัดแบบการรวม (combination therapy) ของแอนทิบอดีอะฟูโคซิเลต CD20 กับ ฟลูดาราบีน (fludarabine) และ/หรือ มิโทแซนโทรน (mitoxantrone)